As the most widely recognized gynecologic danger in the United States of America, endometrial cancer has a growing occurrence that is most likely subordinate only to the obesity epidemic. For endometrial cancer in its early stages, surgery is typically the foremost treatment; this is usually followed by adjuvant therapy in some particular cases. On the basis of the recurrence risk of endometrial cancer, patients are classified into different categories. This helps in determining whether or not the patients will receive chemotherapy along with their radiation therapy (RT). A decrease in locoregional recurrence (LRR) was seen in numerous prospective trials (PORTEC-1, PORTEC-2, and GOG#99) where adjuvant RT was utilized in the intermediate-risk (IR) and high-intermediate risk (HIR). However, no effects were detected in overall survival. From the ad hoc evaluations of these studies, the HIR group was found to have an even greater decrease in LRR risk in comparison to the IR group. Vaginal brachytherapy is pretty much as great as external beam radiotherapy in holding back vaginal relapse which is where most of the recurrence of the disease happens to occur and with much less harmfulness. Multimodality treatment (chemotherapy and RT) may assume a critical part in the high-risk group. Despite the fact that adjuvant RT has been assessed in various cost-efficient studies, there was still a shortage of high-quality information in this area. The take-up of the above forthcoming trial outcomes in the United States was not promising. Future studies need to focus on the factors that drive the present practices and characterize the quality of care of patients diagnosed with early stages of the illness.